| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | 2 | +$40.5K | Bought Aug 19, 26 | |
| Lisa McClain MI09 | 1 | 2 | −$8.0K | Sold Jul 10, 25 |
| Josh Gottheimer NJ05 | 1 | −$8.0K | Trimmed Apr 9, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 19, 26 | Gilbert Cisneros CA31 | Self | Buy | $15,001 - $50,000 | Sep 10, 26 (22d) | |
| Mar 3, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Apr 7, 26 (35d) | |
| Jul 10, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Aug 13, 25 (34d) | |
| Jun 24, 25 | Lisa McClain MI09 | Spouse | Sell (part) | $1,001 - $15,000 | Aug 13, 25 (50d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| Apr 9, 25 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | May 14, 25 (35d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Tobin James RDirector | Sale at price 74.58 per share. | 30K | $2.24M |
| Sep 14, 2026 | Tobin James RDirector | Conversion of Exercise of derivative security at price 53.75 - 63.68 per share. | 30K | $1.76M |
| Aug 17, 2026 | Zarrilli Stephen TDirector | Sale at price 87.04 per share. | 25K | $2.18M |
| Aug 17, 2026 | Zarrilli Stephen TDirector | Conversion of Exercise of derivative security at price 53.27 per share. | 25K | $1.33M |
| Jul 26, 2026 | Davidar David DDirector | Stock Gift at price 0.00 per share. | 2.5K | — |
| Jun 4, 2026 | Davidar David DDirector | Sale at price 80.76 per share. | 25K | $2.02M |
| Jun 4, 2026 | Davidar David DDirector | Conversion of Exercise of derivative security at price 26.27 per share. | 25K | $656.75K |
| Jun 3, 2026 | Rhoads Ann DDirector | Conversion of Exercise of derivative security at price 26.27 per share. | 25K | $656.75K |
| Feb 24, 2026 | Huller Kelly GraceGeneral Counsel | Sale at price 94.50 per share. | 20K | $1.89M |
| Feb 24, 2026 | Huller Kelly GraceGeneral Counsel | Conversion of Exercise of derivative security at price 43.58 per share. | 20K | $871.60K |
| Feb 11, 2026 | Huller Kelly GraceGeneral Counsel | Sale at price 87.67 per share. | 10K | $876.70K |
| Feb 11, 2026 | Huller Kelly GraceGeneral Counsel | Conversion of Exercise of derivative security at price 45.64 per share. | 10K | $456.40K |
| Jan 7, 2026 | Kline KyleChief Financial Officer | Sale at price 101.10 per share. | 3.6K | $363.35K |
| Jan 7, 2026 | Norwalk Leslie VDirector | Sale at price 101.10 per share. | 2K | $202.20K |
| Jan 7, 2026 | Kline KyleChief Financial Officer | Conversion of Exercise of derivative security at price 51.87 per share. | 3.6K | $186.42K |
| Dec 11, 2025 | Norwalk Leslie VDirector | Sale at price 88.85 per share. | 4K | $355.40K |
| Dec 7, 2025 | Paul David COfficer, Director and Beneficial Owner | Conversion of Exercise of derivative security at price 25.52 per share. | 34.4K | $877.25K |
| Nov 30, 2025 | Kline KyleChief Financial Officer | Sale at price 90.00 per share. | 18.5K | $1.67M |
| Nov 30, 2025 | Kline KyleChief Financial Officer | Conversion of Exercise of derivative security at price 53.14 - 64.44 per share. | 18.5K | $1.11M |
| Nov 24, 2025 | Huller Kelly GraceGeneral Counsel | Sale at price 90.00 per share. | 7.5K | $675.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.9 | 5.3 | -9.7 | 4.7 | -9.2 | -3.5 | -0.3 | 3.3 | -8.0 | 1.8 | −12.7% | ||
| 2025 | 12.1 | -13.4 | -8.9 | -2.0 | -17.5 | -0.3 | -10.8 | 16.4 | -6.5 | 5.4 | 50.8 | -4.1 | +5.6% |
| 2024 | -0.9 | 2.3 | -0.6 | -7.2 | 34.8 | 2.1 | 5.1 | 1.0 | -1.6 | 2.8 | 16.4 | -3.4 | +55.2% |
| 2023 | 1.7 | -22.7 | -2.9 | 2.6 | -6.9 | 10.0 | 1.2 | -10.2 | -8.2 | -7.9 | -1.7 | 18.6 | −28.2% |
| 2022 | -7.6 | 5.4 | 4.9 | -10.2 | 0.6 | -15.7 | 4.5 | 0.9 | 0.6 | 12.5 | 10.3 | 0.5 | +2.9% |
| 2021 | -5.4 | 1.3 | -1.3 | 16.4 | 0.4 | 7.6 | 7.3 | -1.9 | -6.1 | 0.7 | -18.9 | 15.3 | +10.7% |
| 2020 | -11.2 | -13.5 | -6.0 | 11.6 | 15.1 | -12.7 | 1.0 | 17.3 | -12.4 | 5.3 | 15.3 | 8.6 | +10.8% |
| 2019 | 4.1 | 8.1 | 1.5 | -8.7 | -12.8 | 7.6 | 7.8 | 12.0 | 0.1 | 2.4 | 6.8 | 5.2 | +36.0% |
| 2018 | 12.0 | 3.5 | 4.6 | 2.7 | 8.5 | -9.2 | 2.0 | 3.5 | 6.6 | -6.9 | -8.6 | -10.4 | +5.3% |
| 2017 | 6.2 | 5.5 | 6.5 | 2.4 | 1.4 | 7.8 | -7.2 | -1.7 | -1.7 | 7.2 | 19.3 | 8.1 | +65.7% |
| 2016 | -10.3 | -2.6 | -2.3 | 5.4 | -3.2 | -1.7 | -3.7 | 1.2 | -2.8 | -1.9 | -2.2 | 14.6 | −10.8% |
| 2015 | -0.8 | 3.0 | 4.0 | -5.3 | 8.6 | -1.0 | 9.3 | -13.0 | -15.4 | 8.2 | 21.4 | 2.5 | +17.0% |
| 2014 | 16.0 | 1.1 | 12.4 | -8.2 | -1.0 | -1.1 | -6.8 | -18.7 | 8.4 | 12.7 | 3.9 | 3.2 | +17.8% |
| 2013 | 21.8 | 13.1 | 1.6 | 3.7 | -4.1 | 15.5 | -0.6 | 5.1 | -0.9 | 10.0 | 0.3 | 4.8 | +92.4% |
| 2012 | 13.3 | -4.8 | -22.4 | -21.2 | −34.1% |
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Buy / hold / sell counts